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Abstract
Introduction: Cartilage oligomeric matrix protein (COMP) is found at elevated concentrations in sera of patients
with joint diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA). We recently showed that COMP
activates complement via the alternative pathway and that COMP-C3b complexes are present in sera of RA
patients, but not in healthy controls. We now set out to elaborate on the information provided by this marker in a
variety of diseases and larger patient cohorts.
Methods: COMP-C3b levels in sera were measured by using an enzyme-linked immunosorbent assay (ELISA)
capturing COMP and detecting C3b. Serum COMP was measured by using ELISA.
Results: COMP-C3b levels were significantly elevated in patients with RA as well as in systemic lupus
erythematosus (SLE), compared with healthy controls. SLE patients with arthritis had significantly higher COMP-C3b
levels than did those without. COMP-C3b was furthermore elevated in patients with ankylosing spondylitis (AS),
psoriatic arthritis (PsA), reactive arthritis, systemic sclerosis, and OA. COMP-C3b did not correlate with COMP in any
of the patient groups. COMP-C3b correlated with disease activity in RA, but not in other diseases. COMP-C3b levels
in RA patients decreased on treatment with tumor necrosis factor (TNF)-a inhibitors, whereas the levels increased
in patients with AS or PsA. The changes of COMP-C3b did not parallel the changes of C-reactive protein (CRP).
Conclusions: COMP-C3b levels are elevated in several rheumatologic diseases and correlate with inflammatory
measures in RA. COMP-C3b levels in RA decrease during TNF-a inhibition differently from those of CRP, suggesting
that formation of COMP-C3b relates to disease features not reflected by general inflammation measures.
Introduction
Rheumatoid arthritis (RA) is a disabling disease with
both a large impact on the quality of life for the patient
and a high economic impact on society. It is known that
early intervention minimizes tissue damage and disease
progression. Therefore specific and sensitive diagnostics
are essential for early discovery of disease. Even though
rheumatoid factor (RF) and anti-citrullinated peptide
antibodies (ACPAs) are widely used as diagnostics for
RA, improvements are needed to enhance the specificity
and sensitivity of current molecular markers in RA.
Therapy should also improve when new diagnostic
assays can differentiate RA patients into groups with
different underlying pathologic mechanisms. Several
approaches to develop novel serologic markers for RA
have been attempted, one of them being measurement
of cartilage oligomeric matrix protein (COMP) in serum
or synovial fluid. COMP is a structural component of
cartilage, and it has been shown to be released during
erosive joint diseases such as RA and osteoarthritis
(OA) [1]. Excessive production of COMP in the skin in
systemic sclerosis (SSc) is also reflected by an increase
in serum COMP [2]. COMP is a homopentamer of 435
kDa in which each individual monomer is composed of
four epidermal growth factor (EGF) domains, eight
thrombospondin type 3 (TSP3) domains, and a globular
C-terminus. The chains polymerize via their N-terminal
coiled coil domains, and this is stabilized by interchain
disulfide bonds [3]. One function of COMP in tissue is
to catalyze collagen fibrillogenesis [4,5] and, in the
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adult, to stabilize tissue structure by interacting with
other collagen-bound matrix proteins [6].
In a previous study, we showed that COMP released
from the joints during RA is able to activate comple-
ment both in vitro and in vivo [7]. Complexes between
COMP and the complement-activation product C3b
were found both in the serum and synovial fluid of RA
patients, whereas no COMP-C3b was found in the
serum of healthy controls or in patients with OA; there-
fore, it was concluded that COMP-C3b might be diag-
nostic in RA. The complement-activating site was
shown to reside within the C-terminal proportion of
COMP, by interaction with both properdin and C3.
Complement is an important part of innate immunity,
and its uncontrolled activation has been strongly impli-
cated in many autoimmune diseases, among them, RA.
Several studies have shown that complement deficiency
or inhibition ameliorates disease activity in rodent mod-
els of RA [8,9], and complement-activation products
have been found in the joints of patients with RA
[10-12]. Several proteins that are found in affected joints
have been shown to activate complement, among them
RF [13,14], ACPA [15], cartilage molecules of the small
leucine-rich-repeat protein (SLRP) family [16,17], as well
as apoptotic cells [18] and thereby most likely contri-
bute to disease progression by feeding the inflammatory
response. Measurement of complexes between comple-
ment-activation products and joint-specific molecules
might provide improved specificity to the diagnostics of
RA and may give better distinction between patients
with complement-mediated joint inflammation and
healthy individuals. This might also provide valuable
information on the patients’ need of complement-inhibi-
tion therapy that is currently undergoing clinical trials.
Our previous pilot study on the presence of COMP-
C3b in the circulation of RA and OA patients, as well as
in healthy controls, was conducted on a small number
of patients, and therefore, in the present study, we set
out to validate our results in larger patient cohorts. To
investigate whether such complexes are a specific fea-
ture of RA or whether they can be found in patients
with other rheumatologic disorders or joint diseases, we
have now included patients with SSc, reactive arthritis
(ReA), psoriatic arthritis (PsA), ankylosing spondylitis
(AS), and systemic lupus erythematosus (SLE), as well as
a larger group of healthy individuals. Furthermore, we
have also related serum concentrations of COMP-C3b
complexes to clinical and biochemical markers com-
monly used to monitor disease activity, as well as stu-
died changes of COMP-C3b levels over a 3-month
period in relation to treatment of RA, PsA, or AS with
TNF inhibitors to elucidate how changes relate to mod-
ulation of disease activity.
Materials and methods
Patients and controls
The study was approved by the Ethical Review Board
at Lund University. Table 1 describes some character-
istics of the patients and controls. All serum samples
were retrieved in a similar, standardized fashion (non-
fasting) and were stored in -80°C after centrifugation.
Samples from 98 RA patients were taken immediately
before initiation of TNF-a inhibition. Of these, sam-
ples from 90 patients were also available after 6 and 12
weeks of treatment. All patients fulfilled the 1987 ACR
criteria for RA [19]. Samples from 58 patients with
symptomatic, radiographically verified knee OA with
uni- or bilateral Kellgren-Lawrence grade 3 or more
were retrieved before enrollment in a study of physical
exercise [20]. Samples from 13 patients with ReA were
obtained in connection with a knee-joint aspiration
due to synovitis. Samples from 30 patients with PsA or
AS were obtained immediately before initiation of
TNF-a inhibition. Diagnosis of ReA, PsA, or AS was
based on clinical judgment by the treating physician
and included radiographic examinations when applic-
able. The patient charts of the ReA patients were
examined to exclude alternative diagnoses. All AS
patients had axial involvement but no clinical signs of
peripheral arthritis, whereas the PsA patients had per-
ipheral arthritis but no clinical signs of axial involve-
ment. From the majority of these patients, samples
were also available after 6 and 12 weeks of TNF-a
inhibition.
The 40 patients with SSc all fulfilled the ACR criteria
for SSc [21]. The disease was classified as diffuse cuta-
neous SSc (dcSSc; n = 30) or limited cutaneous SSc
(lcSSc; n = 10) according to the extent of skin involve-
ment [22]. Skin involvement was determined by the
modified Rodnan skin score (mRSS) [23]. The disease
onset was defined as the first non-Raynaud manifesta-
tion. The 56 SLE patients included in the study fulfilled
four or more ACR classification criteria [24]. Disease
activity was evaluated by using SLEDAI-2K (SLE disease
activity index) [25]. Thirty patients had no clinical dis-
ease activity and were in remission. Twenty-six patients
had clinical disease activity, defined as a flare, at the
time of blood sampling. The SLEDAI score at this time
varied between 2 and 20. Routine laboratory tests were
used to assess disease activity, including concentration
of complement components (C3, C4, and C1q) as well
as presence of antibodies against dsDNA, C1q, SS-A,
and SS-B. Ninety-seven healthy volunteers with no his-
tory of rheumatologic disease were selected for the
study as a control group. Sera from these individuals
were collected in Lund and in Malmö, according to
standard procedures, as described for the patients.
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Informed consent was obtained from all participants
involved in the study.
Measuring COMP and COMP-C3b complexes in serum
Serum COMP concentrations were measured with a
commercially available COMP ELISA (AnaMar, Lund,
Sweden). The presence of soluble COMP-C3b com-
plexes in biologic samples was measured with a sand-
wich-ELISA based on the COMP ELISA plate. Serum
was diluted 1:10 in the sample buffer provided with the
kit, and a 50-μl sample was added to the provided anti-
COMP-coated plates. As an internal reference sample,
50 μl of the 1.7 U/L calibrator diluted 1:2 in sample buf-
fer was added to duplicate wells on the plate. Incubation
was at room temperature for 2 hours, after which plates
were washed 4 times with the washing buffer provided
in the kit. A biotinylated polyclonal anti-C3d antibody
(A0063; Dako) diluted 1:1,000 in the conjugate buffer of
the kit, was added to the wells, and the plates were
incubated for 1 hour at room temperature. After wash-
ing as described earlier, HRP-conjugated streptavidin
(21130; Pierce) was diluted 1:60,000 in the conjugate
buffer and incubated with the plate for 1 hour at room
temperature. After washing 4 times, bound complexes
were detected according to the protocol of the COMP
ELISA. The recorded absorbance of each sample was
normalized by setting the mean absorbance of the inter-
nal reference to 1 (450 nm; Cary 50 MPR microplate
reader, Varian). All samples were measured in duplicate,
and values are expressed as arbitrary units (AUs).
The presence of rheumatoid factor does not interfere
with the assay because a biotinylated primary antibody
in combination with a streptavidin/HRP-conjugate is
used to avoid secondary antibodies. Therefore, any rheu-
matoid factors present that might recognize the murine-
catching antibody will not generate signal in the detec-
tion step. In support of this, we found no correlation
between the presence of rheumatoid factor and level of
COMP-C3b in sera.
Biotinylation of antibodies
The polyclonal anti-C3d antibody (A0063; Dako) was
biotinylated by using biotin-amidohexanoic acid-N-
hydroxysuccimide ester (B2643; Sigma). In brief, the
antibody was incubated with biotin-amidohexanoic acid-
N-hydroxysuccimide ester in 0.1 M borate buffer, pH
8.0, overnight at +4°C at a ratio of 0.5 mg biotinylation
reagent per 1 mg antibody. The reaction was stopped by
adding solid glycine to the mixture to a final concentra-
tion of 4 mg/ml. The antibody was dialyzed extensively
against TBS, and successful biotinylation was confirmed
by subjecting the sample to Western blot with a strepta-
vidin-HRP conjugate (21130; Pierce).
Statistical analysis
The differences in COMP and COMP-C3b concentra-
tions between disease groups were analyzed by using a
Kruskal-Wallis test and a Dunn Multiple Comparison
posttest. Two-group comparisons were conducted by
using a Mann-Whitney U test. The Friedman test was
used to calculate statistically significant changes in
inflammatory parameters on TNF-a inhibition in the
RA patients. Because of missing values for both the AS
and PsA patients at 6 weeks and 3 months, we used a
Wilcoxon matched-pairs test to include more observa-
tions in the analysis of these groups. Two-parameter
Table 1 Description of patients and controls
RA OA ReA PsA AS SSc SLE Control
Number 98 58 13 30 30 40 56 97
Gender
(F:M)








































































































*Values denote median and range, except for gender and tumor necrosis factor (TNF)-a inhibitor. AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA,
rheumatoid arthritis; OA, osteoarthritis; ReA, reactive arthritis; SLE, systemic lupus erythematosus SSc, systemic sclerosis.
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correlations were conducted with Spearman correlation
analysis.
Results
Elevated COMP-C3b is found in several rheumatologic
diseases
COMP-C3b concentrations were significantly elevated in
the serum of RA patients compared with healthy con-
trols (P < 0.001), corroborating and extending previously
published results (Figure 1a and Table 1) [7]. In contrast
to earlier findings, the OA patients in this study cohort
displayed high COMP-C3b concentrations in their sera
(P < 0.001), although, as for RA patients, the scatter
between the individuals was relatively large. High
COMP-C3b concentrations were also found in the sera
of patients with SSc, ReA, and SLE (P < 0.001). Patients
with PsA and AS had moderately elevated levels of
serum COMP-C3b (P < 0.05). Applying a cut-off value
represented by the median + 2SD from the control
group, 43.9% of RA, 77.6% of OA, 84.6% of ReA, 20% of
PsA, 6.7% of AS, 67.9% of SLE, 87.5% of SSc patients,
and 5.2% of healthy controls tested positive for COMP-
C3b.
Elevated COMP levels were found only in patients
with RA, SSc, and OA (P < 0.001), compared with
healthy controls (Figure 1b and Table 1). No correlation
was found between serum COMP and COMP-C3b in
any of the patient groups. No difference in COMP-C3b
values were observed between male and female subjects
in any of the disease groups.
COMP-C3b correlates with disease activity in RA
COMP-C3b was found to correlate to several measures
reflecting disease activity in RA. A positive correlation
was found between COMP-C3b and the disease-activity
score (DAS28-ESR or CRP-based) (Table 2). Further-
more, COMP-C3b correlated with the individual items
of DAS28 (that is, C-reactive protein (CRP), the 28
swollen and tender joint counts, and the erythrocyte
sedimentation rate (ESR)). The fact that these correla-
tions are relatively weak suggests that even though the
serum concentration of COMP-C3b relates to disease
activity, it reflects features of the disease process not
measured by traditional inflammatory variables. No cor-
relation was found between COMP-C3b and the visual
analogue scale (VAS) global assessment score or pain
rated on VAS in RA patients.
Interestingly, but not unexpectedly, COMP-C3b did
not correlate with the DAS28 in patients with PsA (rs =
0.3106; P = 0.0948) or AS (rs = 0.2400; P = 0.2015). No
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Figure 1 Serum COMP-C3b and COMP in patients with
rheumatologic diseases. Serum COMP-C3b (a) and COMP (b)
were measured in patients with different rheumatologic diseases.
The horizontal bar indicates the median of each group. Statistical
significance of differences between disease groups and controls was
measured by using a Kruskal-Wallis test with a Dunn multiple
comparison posttest. ***P < 0.001; **P < 0.01; *P < 0.05; ns, not
significant.
Table 2 Correlation of COMP-C3b with clinical variables
in RA






28 swollen joints 0.2109 0.0371
28 tender joints 0.2313 0.0220
ESR 0.3556 0.0004
Hb -0.2289 0.0256
VAS global 0.0863 0.3983
VAS pain 0.1413 0.1652
CDAI, clinical disease activity index; CRP, C-reactive protein; DAS, disease
activity score; ESR, erythrocyte sedimentation rate; Hb, hemoglobin
concentration; SDAI, simplified disease activity index; VAS, visual analogue
scale.
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VAS global-assessment score or pain rated on VAS in
AS (global-assessment score; rs = -0.0956; P = 0.6152;
pain; rs = 0.1064; p = 0.5758) or PsA (global-assessment
score; rs = 0.0084; P = 0.9650; pain; rs = 0.2326; P =
0.2162). Moreover, no correlation was found between
CRP and COMP-C3b in these disease groups (PsA, rs =
0.2672; P = 0.1534; and AS, rs = 0.1198; P = 0.5358).
Therefore it seems that circulating COMP-C3b is not
closely linked to disease activity in these patient groups.
No significant correlation was found between COMP-
C3b and ESR in ReA (rs = 0.54555; P = 0.0876), possibly
because of the relatively few patients in this group.
However, in SSc patients, a weak correlation was found
between COMP-C3b and CRP (rs = 0.5246; P = 0.0306).
COMP-C3b did not correlate with the ESR (rs = 0.146;
P = 0.312) in OA patients.
COMP-C3b in SLE
The levels of COMP-C3b in SLE patients were increased
compared with healthy controls, but no difference was
noted in serum COMP-C3b or COMP between SLE
patients in flare or in remission (Figure 2a, b). However,
SLE patients with arthritis as a part of the disease flare
at the time of sampling had significantly higher serum
COMP-C3b concentrations than did patients without
arthritis (Figure 2c). Patients who at any time of the dis-
ease course had had arthritis showed, in general, slightly
higher COMP-C3b values in their sera compared with
patients that never had arthritis, although this did not
reach statistical significance. No correlations were
apparent for any other SLE disease phenotypes (such as,
for example, nephritis, when investigating the ACR cri-
teria for SLE (data not shown). During disease flare in
SLE, a strong positive correlation occurred between
COMP-C3b and complement components C1q and C4,
but no correlation between COMP-C3b and C3 (Figure
2d through f). Even though SLE patients displayed rela-
tively low COMP concentrations in serum, they had sig-
nificantly elevated amounts of COMP-C3b in the
circulation, comparable to those in RA patients (Figure
1a, b). This may suggest that the fragments of COMP
released in SLE particularly represent those that can
activate complement. This is in contrast to other studied
disease groups in which the ratio between circulating
COMP-C3b and COMP was much lower; the only inter-
esting exception was patients with ReA who also had
relatively high levels of serum COMP-C3b compared
with COMP.
COMP-C3b decreases in RA patients with TNF-a inhibition
TNF-a inhibition has been shown to reduce serum
COMP levels in patients with RA [26]. As we showed
that COMP-C3b reflects disease activity in RA patients,






























































































Figure 2 COMP-C3b in SLE patients. Comparison of serum COMP-C3b (a) and COMP (b) in systemic lupus erythematosus (SLE) patients
during remission (n = 30) and flare (n = 26). SLE patients with arthritis during flare (n = 11) have higher COMP-C3b than do patients without
arthritis during flare (n = 15) (c). Correlation between COMP-C3b and C1q (d), C4 (e), C3 (f) in SLE patients during flare was measured by using
the Spearman correlation analysis.
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reduce the serum COMP-C3b concentrations. Samples
collected from 90 RA patients were measured for serum
COMP-C3b, COMP, and CRP at baseline, after 6 weeks,
or after 3 months of infliximab treatment. No significant
difference was noted between baseline COMP-C3b and
the 6-week values, whereas COMP-C3b was significantly
reduced after 3 months of treatment (Figure 3a). Nota-
bly, the decrease in COMP-C3b was marked in some
patients, whereas the levels remained unchanged in
others. CRP levels were reduced in the majority of
patients already after 6 weeks of treatment compared
with baseline and remained low at 3 months (Figure
3b). Therefore, it seems that the decreases in CRP levels
and COMP-C3b follow different kinetics, with reduction
in COMP-C3b being observed at a later stage. However,
COMP-C3b still correlated with CRP at 6 weeks (rs =
0.3531; P = 0.001) and 3 months (rs = 0.388; P = 0.001).
Serum COMP values remained unchanged in these
patients even at 3 months, for reasons still not known.
One possible explanation is the relatively low baseline
COMP values in this cohort (Figure 3c).
COMP-C3b increases in PsA and AS patients with TNF-a
inhibition
Interestingly, in PsA patients receiving TNF-a inhibition
therapy, serum COMP-C3b was increased after 6 weeks
compared with baseline and remained elevated at 3
months of treatment (Figure 4a). CRP levels in these
patients decreased as expected after 6 weeks of treat-
ment compared with baseline, and a slight increase was
observed again at 3 months (Figure 4b). A similar pat-
tern was seen for AS patients receiving TNF-a inhibi-
tion therapy; COMP-C3b increased at week 6 compared
with baseline, and a statistically insignificant decrease
was observed at 3 months (Figure 4d). In line with the
findings for PsA patients, in AS, the CRP levels had
already stabilized at a low level by week 6 and remained
low at 3 months (Figure 4e). Serum COMP levels
remained unchanged in the PsA group during treat-
ment, whereas they increased in the AS group (Figure
4c and 4f, respectively). Taken together, this suggests
that COMP-C3b does not closely relate to ongoing
inflammation in these diseases.
Discussion
In the present study, we showed that elevated COMP-
C3b can be found in the circulation of RA patients,
extending previous observations in a smaller patient
cohort. COMP-C3b correlates with several inflammatory
parameters describing mainly synovitis in RA, suggesting
that joint inflammation causes the release of COMP
fragments that are able to activate complement. Interest-
ingly, with TNF-a inhibition, serum COMP-C3b
decreased significantly, which indicates that the molecu-
lar process of cartilage turnover has been altered.
Because serum COMP did not significantly decrease
during TNF-a inhibition, it appears that the interven-
tion causes a reduction in the release of complement-
activating COMP, perhaps in the form of unique frag-
ments, as opposed to a reduction in total COMP. This
might be a process of modified cartilage degradation or
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Figure 3 COMP-C3b decreases in rheumatoid arthritis (RA)
patients on tumor necrosis factor (TNF)-a inhibition. RA patients
(n = 90) receiving infliximab were measured for COMP-C3b (a), C-
reactive protein (CRP) (b), and COMP (c) at baseline, after 6 weeks,
and after 3 months of treatment. Statistical significance of changes
in these parameters was measured with a Friedman test. ***P <
0.001; **P < 0.01; *P < 0.05; ns, not significant.
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previous study reported that serum COMP levels
decreased on TNF-a inhibition [26]. The fact that this
decrease was not seen in our patient cohort might be a
reflection of the lower baseline COMP values in our
cohort (9.1 U/L) compared with the other cohort (11.3
U/L and 12.2 U/L in the different treatment groups).
Furthermore, in the other study, the major reduction
was seen in the patients with the highest baseline
COMP values.
The reduction in CRP levels and COMP-C3b were
observed to follow different kinetics, with a decrease in
COMP-C3b occurring at a slower rate. This indicates
that formation of COMP-C3b is not an immediate
response to inflammation-induced joint damage but
rather a complicated process regulated by cartilage
metabolic and catabolic activity and by the surrounding
microenvironment.
The AS patients in our cohort, who were chosen for
having only axial joint involvement, had slightly higher
concentrations of circulating COMP-C3b than did the
controls. Interestingly, in this group, CRP did not corre-
late with COMP-C3b. Similar observations were made
for patients with peripheral joint PsA, in which a lack of
correlation between CRP and COMP-C3b was also
observed. The fact that both groups had similar levels of
circulating complexes indicates that the origin of
released COMP fragments (axial/peripheral joints) does
not directly relate to the ability of COMP to activate
C3. Furthermore, lack of correlation between CRP and
these complexes shows that the level of COMP-C3b in
these patient groups does not reflect disease activity.
Surprisingly, an increased COMP-C3b was observed in
both AS and PsA patients on TNF-a inhibition, even
though systemic inflammation was reduced, as shown
by a decrease in CRP. Therefore, it is possible that this
intervention either stimulates tissue regeneration or
changes the character of the COMP fragments released
from the tissue. It also is possible that TNF-a inhibition
is effective downstream of the process of tissue destruc-
tion and complement activation and therefore will pri-
marily have an effect on the inflammation, its
symptoms, and effects.
In the current study, we observed elevated levels of
COMP-C3b in the sera of OA patients, in contrast to
our previous report, in which this was observed only in
the synovial fluid and not in serum. With further inves-
tigations of this divergence, we found that, for unex-






































































































































Figure 4 Serum COMP-C3b increases in patients with ankylosing spondylitis (AS) and PsA on tumor necrosis factor (TNF)-a inhibition.
Serum COMP-C3b (a), C-reactive protein (CRP) (b), and COMP (c) were measured in patients with PsA receiving TNF-a inhibition at baseline,
after 6 weeks of treatment, and after 3 months of treatment. COMP-C3b (d), CRP (e), and COMP (f) were also measured in AS patients receiving
TNF-a inhibition at the same times. Statistical significance of changes in these parameters was measured with a Wilcoxon matched-pairs test
because of many missing values at the time point, 3 months. ***P < 0.001; **P < 0.01; *P < 0.05; ns, not significant.
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used, all C3 was degraded to fragments smaller than 40
kDa, as shown by SDS-PAGE followed by Western blot-
ting. Thus, the fraction of C3b that, in the patient, was
deposited onto COMP was most likely similarly
degraded and therefore unrecognizable in our assay. We
found that this was not the case for the synovial fluid
samples. We are not sure what caused the degradation
of C3 in the archival OA samples during storage. We
have found experimentally that serum can be thawed
and frozen several times or stored for many hours at
room temperature before freezing without C3 becoming
degraded, and thus no extreme precautions must be
taken for the sample to be suitable for analysis with our
assay. However, the OA serum samples used in the pre-
vious study were obviously exposed to some harsh con-
ditions that were not apparent to any co-authors but
could have occurred during the many years during
which these samples were stored. We confirmed that C3
was not degraded in any other patient group or in OA
samples used in the current study. The new data clearly
show that at least a proportion of the COMP released in
OA contains the complement-activating region in the C-
terminal part. It is important to stress that, even though
the inflammation is much more pronounced in RA, an
inflammatory component also exists in OA [27,28].
Patients with SSc displayed in previous studies ele-
vated COMP levels in their circulation as a result of
increased COMP synthesis and turnover by their dermal
fibroblasts [2]. We could now observe elevated levels of
COMP-C3b in their circulation as well, which shows
that the released COMP fragments have the potential to
activate complement. Furthermore, patients with ReA
displayed high levels of COMP-C3b in their circulation.
The median COMP-C3b values in ReA were markedly
higher than those in other studied disease groups, which
most likely reflects the pronounced cartilage engage-
ment and strong inflammatory stimulation of the dis-
ease. Similarly, SLE patients were found to have elevated
levels of COMP-C3b in their circulation, independent of
being in disease flare or remission. The serum COMP-
C3b concentration was, however, significantly higher in
patients with arthritis than in patients without arthritis,
suggesting the importance of joint inflammation and
possibly cartilage involvement for the release of comple-
ment-activating COMP. The fact that C1q and C4 levels
were positively correlated with COMP-C3b shows that
classic pathway components are not consumed during
the disease process leading to COMP-C3b formation.
Even though a negative correlation could be expected
between COMP-C3b and C3, it might be that the over-
whelming excess of C3 in serum compared with released
COMP masks such changes. However, we cannot
exclude that C3 has been consumed within the synovial
fluid as a more-local response.
Conclusions
We found elevated levels of COMP-C3b complexes in
the circulation of patients with several rheumatologic
diseases, showing that the release of complement-acti-
vating COMP is not a specific feature of RA. Because
levels of COMP-C3b correlate to the inflammatory vari-
ables in RA but not in the other diseases examined, it
seems that formation and release of complexes can
reflect somewhat different processes in different condi-
tions. This may relate to downstream regulation of the
inflammatory process and merits further investigation.
Notably, TNF-a inhibition in RA reduced COMP-C3b
serum levels in RA, but not in AS and PsA, which
points to different pathophysiologic mechanisms regulat-
ing complex formation. It should be stressed that
although a correlation was found to inflammation in
RA, this was rather weak and, taken together with the
different kinetics of response for CRP and COMP-C3b
complexes after TNF-a inhibition, may suggest that the
release of complexes is not merely due to inflammation
but reflects other, yet unknown components of the dis-
ease process in RA (for example, being upstream of
major cytokine release). Further studies, including longi-
tudinal monitoring of early RA patients, are needed to
elucidate the pathophysiologic role of COMP-C3b com-
plexes and to establish their value as disease markers in
the clinic.
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